Abstract

**Background:** Night shift work has been associated with higher risks of breast and endometrial cancer, but few studies have evaluated associations with other reproductive cancers.

**Methods:** We examined the association between rotating night shift work and risk of ovarian cancer during 20 years of follow-up in 181,548 women participating in two large cohort studies, the Nurses’ Health Study (NHS) and NHSII. Number of years of rotating night shift work was queried in 1988 for NHS and in 1989, 1991, 1993, 2001, and 2005 for NHSII. We used Cox proportional hazards regression to model HRs and 95% CIs of ovarian cancer for each shift work category (1–2, 3–5, 6–9, 10–14, 15–19, and 20+ years).

**Results:** We confirmed 718 incident cases of ovarian cancer over 2,974,672 person-years of follow-up. Rotating shift work was not associated with ovarian cancer risk in either cohort individually. Combining both cohorts, compared with women without any night work, the HR for 15 to 19 years of rotating night shift work was 1.28 (95% CI: 0.84–1.94) and for 20+ years 0.80 (95% CI: 0.51–1.23).

**Conclusions:** In this large prospective study, there was no association between duration of rotating night shift work and risk of ovarian cancer.

**Impact:** Although associated with other cancers, night shift work does not appear to be associated with increased risk of ovarian cancer. However, further exploration of the association between melatonin and risk of ovarian cancer is warranted. Cancer Epidemiol Biomarkers Prev; 20(5); 934–8. ©2011 AACR.

Introduction

Night shift work has been associated with increased risks of multiple cancer types (1–12), including hormonally sensitive cancers such as breast (1–7) and endometrial (8) cancers, prompting the International Agency for Research on Cancer to classify night shift work as a probable carcinogen (13). Night shift work may be linked to cancer risk by the diminished ability of the pineal gland to produce melatonin among those exposed to light at night (14). There are likely several anticancer mechanisms for melatonin (reviewed in ref. 15) including modulation of estradiol levels and aromatase activity and downregulation of ERα (estrogen receptor) expression in mammary tumors.

Animal and experimental studies suggest a chemoprotective role of melatonin specifically in ovarian carcinogenesis. Treatment of ovarian cancer cell lines with melatonin resulted in growth inhibition (16). Furthermore, in turkey breeder hens with ovarian adenocar-
Ascertainment of night shift working status

In 1988, NHS participants were asked how many total years they had worked rotating night shifts at least 3 nights per month in addition to day or evening shifts. Duration of rotating night shift work was ascertained in the following prespecified categories: never, 1–2, 3–5, 6–9, 10–14, 15–19, 20–29, and 30+ years. Of the 103,614 participants who responded to the 1988 questionnaire, 85,197 answered the shift work question. The majority (91.8%) who did not answer the shift work question received a shortened questionnaire that did not contain the shift work question. Among those who received the long version of the questionnaire, the follow-up rate through June 2008 was 86.5% of the potential person-years.

NHSII participants were first asked about their duration of rotating night shift work in 1989 in the following prespecified categories: 1–2, 3–5, 6–9, 10–14, 15–19, and 20+ years. This information was updated in 1991, 1993, 2001, and 2005. In each cycle in which shift work was assessed, duration was obtained since the prior update and used to update the total shift work variable. Of the 116,430 women who responded to the 1989 questionnaire, 115,841 answered the shift work question. The follow-up rate of the NHSII cohort through June 2007 was 87.6% of the potential person-years. If a nurse failed to respond to one of the shift work questions, her previous duration was carried forward.

Documentation of ovarian cancer cases and deaths

We collected information about new ovarian cancer diagnoses on each questionnaire. For all reported cases and deaths due to ovarian cancer identified by family members, the National Death Index, or the U.S. Postal Service, we obtained medical records pertaining to the ovarian cancer diagnosis. A gynecologic pathologist blinded to exposure status reviewed the medical records to confirm the diagnosis, as well as stage, histology, and invasiveness. In a subset of 215 ovarian cancer cases, concordance between the medical records and the pathologist’s review was 98% for invasiveness and 83% for histologic type (21).

Statistical analysis

The eligible population for this analysis included the 85,197 NHS participants who answered the rotating shift work question on the 1988 questionnaire and the 115,841 NHSII participants who answered the same question on the 1989 questionnaire. Women with a cancer (except nonmelanoma skin cancer) diagnosis prior to the baseline year (NHS = 2,977; NHSII = 1,038), a bilateral oophorectomy (NHS = 13,036; NHSII = 2,224), menopause due to pelvic irradiation (NHS = 150; NHSII = 30), or who were missing date of birth (NHS = 35) were excluded. After all exclusions, a total of 68,999 NHS and 112,549 NHSII participants were left in the analyses. Participants accrued person-time from the time of the return of the 1988/1989 questionnaire until the date of ovarian cancer diagnosis, diagnosis of cancer (except nonmelanoma skin cancer), bilateral oophorectomy, pelvic irradiation, death, or the end of follow-up (NHS: June 1, 2008; NHSII: June 1, 2007), whichever occurred first.

We used Cox proportional hazards regression, with age in months and 2-year questionnaire cycle as the time scale, to estimate the HRs and 95% CIs of ovarian cancer for each shift work duration category, compared with those who never worked rotating night shifts, adjusting for known and suspected ovarian cancer risk factors (see Tables for detail). Tests for trend were conducted by treating the shift work duration categories as an ordinal variable and calculating Wald’s statistic.

Data analyses were conducted separately for both cohorts and then pooled using a random effects model to test for heterogeneity (22). To assess whether results varied by menopausal status (pre- vs. postmenopausal), age (<55 vs. 55+ years), postmenopausal hormone (PMH) use (never vs. ever; postmenopausal only), menstrual regularity (no irregularity vs. any irregularity), body mass index (BMI) <25 vs. 25+, or infertility, we included multiplicative interaction terms in multivariate models and tested their significance using Wald’s statistic.

We conducted several sensitivity analyses. First, because duration of shift work was only collected once in NHS, we analyzed NHSII using only the reported baseline shift work duration, in addition to our primary analyses in which we updated shift work information. In addition, because there were so few cases in the higher duration categories, we analyzed the data in categories of none, 1–5, 6–14, and 15+ years. We also conducted an analysis censoring all women who did not respond to the shift work questions after baseline (in NHSII). Finally, we conducted both a 2- and 4-year lag analysis to account for potential healthy worker effects.

Results

At the midpoint of follow-up, 41.0% of the NHS participants and 32.2% of NHSII participants reported never having worked rotating night shifts. Women who reported never working night shifts generally were similar to women who reported night shift work, except that those who had worked rotating night shifts for at least 20 years were older, had a higher BMI, and were more likely to smoke (Table 1).

Combining both cohorts, there was no association between duration of rotating night shift work and risk of ovarian cancer (e.g., 15–19 years, HR: 1.28; 95% CI: 0.84–1.94; 20+ years, HR: 0.80; 95% CI: 0.51–1.23; P_trend = 0.74), compared with women without any night work, and results were similar across cohorts (Table 2). Results did not differ when duration categories were collapsed, when a lag of 2 or 4 years was employed between exposure and ovarian cancer diagnosis, when only baseline NHSII duration was used, or when missing NHSII updated shift work duration values were censored (data not shown). The association between duration of rotating...
night shift work and ovarian cancer did not vary by category of age, menopausal status, PMH use, BMI, oral contraceptive use, menstrual irregularity, or infertility.

Discussion

In this large, prospective study of rotating night shift work and risk of ovarian cancer, we observed no association between increasing duration of night shift work and risk. Few previous studies have examined potential associations between shift work and ovarian cancer. In a Norwegian study, no association with ovarian cancer incidence was observed for radio and telegraph operators (standardized incidence ratio: 0.8; 95% CI: 0.3–1.6; ref. 5), many of whom worked night shifts. However, this result was based on only 7 cases. Karasek and colleagues compared serum circadian melatonin profiles between women with genital tract cancers (including ovarian, endometrial, and cervical cancers) with normal volunteers (23). They reported no differences between melatonin profiles of the ovarian cancer patients compared with the normal controls, but their sample size was limited, and melatonin was measured after ovarian cancer diagnosis.

This study has several potential limitations. First, duration of rotating night shift work was only assessed once in NHS (in 1988). It is possible that the true duration of shift work was underestimated for NHS participants. However, in 1996, only 3% of nurses reported any shift work in the past 6 months, indicating that the extent of the misclassification of duration is limited. Also, duration of shift work was only updated every 4 years in NHSII; however, sensitivity analyses using only baseline shift work duration in NHSII showed similar results, suggesting that the effects of potential misclassification were minimal. Nevertheless, the possibility remains that a small proportion of nurses may have been misclassified as to their true duration of rotating night shift work.

Second, rotating night shift work was assessed through self-report and was not confirmed with personnel or hospital records. However, women in this cohort have been shown to accurately report their exposures to many lifestyle and occupational exposures (e.g., refs. 24, 25). Third, we did not collect data on permanent or infrequent rotating (<3 nights per month) night shift work. Although the disruption of melatonin production likely is less severe from these exposures, we cannot rule out the possibility that the observed lack of association in our study could be due to misclassification among a subset of women with different forms of night shift work. However, as breast, colorectal, and endometrial cancers were associated with rotating night shift work in these cohorts (3, 4, 8, 9), the likely degree of misclassification is low.

The strengths of this analysis include the large number of ovarian cancer cases and prospective data collection. Because women were asked about their rotating shift work exposure prior to the diagnosis of ovarian cancer, the likelihood of recall bias is low. Furthermore, we have collected detailed information on many of the potential confounders of the association between rotating night shift work and ovarian cancer risk, such as reproductive history and hormonal therapy, thus reducing the likelihood of uncontrolled confounding in our analysis. In

### Table 1. Age-standardized characteristics of participant in the Nurses’ Health Study (NHS) in 1998 and NHSII in 1999, the midpoint of the follow-up period (1988–2008 for NHS and 1989–2007 for NHSII)

<table>
<thead>
<tr>
<th>Years of shift work</th>
<th>NHS</th>
<th>NHSII</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample size</td>
<td>22,376</td>
<td>2,303</td>
</tr>
<tr>
<td>Means</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>63.8 (7.1)</td>
<td>44.6 (4.6)</td>
</tr>
<tr>
<td>Age at menarche</td>
<td>12.5 (1.4)</td>
<td>12.4 (1.4)</td>
</tr>
<tr>
<td>Duration of oral contraceptive use, y</td>
<td>2.1 (3.5)</td>
<td>3.8 (4.7)</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>26.3 (5.1)</td>
<td>25.9 (5.5)</td>
</tr>
<tr>
<td>Percentage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parous</td>
<td>95</td>
<td>86</td>
</tr>
<tr>
<td>Premenopausal</td>
<td>4</td>
<td>74</td>
</tr>
<tr>
<td>Postmenopausal</td>
<td>93</td>
<td>8</td>
</tr>
<tr>
<td>Family history of ovarian cancer</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Tubal ligation</td>
<td>21</td>
<td>26</td>
</tr>
<tr>
<td>Ever breastfed (among parous women)</td>
<td>63</td>
<td>66</td>
</tr>
<tr>
<td>Current PMH user (among postmenopausal women)</td>
<td>43</td>
<td>54</td>
</tr>
<tr>
<td>Current smoker</td>
<td>10</td>
<td>8</td>
</tr>
</tbody>
</table>

NOTE: Values are means (SD) or percentages and are standardized to the age distribution of the study population. All factors except age and age at menarche were age standardized in 5-year intervals for each cohort.
Table 2. Multivariate HRs and 95% CIs for risk of epithelial ovarian cancer by years of rotating night shift work in NHS and NHSII separately, and combined

<table>
<thead>
<tr>
<th>Years of rotating shift work</th>
<th>NHS Cases</th>
<th>Person-years</th>
<th>Age-adjusted HR</th>
<th>Multivariate a HR (95% CI)</th>
<th>NHSII Cases</th>
<th>Person-years</th>
<th>Age-adjusted HR</th>
<th>Multivariate a HR (95% CI)</th>
<th>NHS and NHSII Cases</th>
<th>Person-years</th>
<th>Age-adjusted HR</th>
<th>Multivariate a HR (95% CI)</th>
<th>P heterogeneity b</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>202</td>
<td>454,004</td>
<td>1.00</td>
<td>1.00 (ref.)</td>
<td>68</td>
<td>602,593</td>
<td>1.00</td>
<td>1.00 (ref.)</td>
<td>270</td>
<td>1,056,596</td>
<td>1.00</td>
<td>1.00 (ref.)</td>
<td>0.97</td>
</tr>
<tr>
<td>1–2</td>
<td>143</td>
<td>270,522</td>
<td>1.20</td>
<td>1.20 (0.97–1.49)</td>
<td>54</td>
<td>591,716</td>
<td>0.82</td>
<td>0.80 (0.56–1.14)</td>
<td>197</td>
<td>862,237</td>
<td>1.08</td>
<td>1.07 (0.89–1.29)</td>
<td>0.06</td>
</tr>
<tr>
<td>3–5</td>
<td>80</td>
<td>183,352</td>
<td>0.96</td>
<td>0.95 (0.73–1.23)</td>
<td>35</td>
<td>386,364</td>
<td>0.82</td>
<td>0.79 (0.52–1.18)</td>
<td>115</td>
<td>568,716</td>
<td>0.93</td>
<td>0.90 (0.72–1.13)</td>
<td>0.46</td>
</tr>
<tr>
<td>6–9</td>
<td>33</td>
<td>74,671</td>
<td>0.98</td>
<td>0.96 (0.67–1.40)</td>
<td>18</td>
<td>178,426</td>
<td>0.89</td>
<td>0.80 (0.47–1.35)</td>
<td>51</td>
<td>253,098</td>
<td>0.96</td>
<td>0.92 (0.68–1.25)</td>
<td>0.55</td>
</tr>
<tr>
<td>10–14</td>
<td>25</td>
<td>48,771</td>
<td>1.12</td>
<td>1.06 (0.70–1.62)</td>
<td>14</td>
<td>76,496</td>
<td>1.42</td>
<td>1.25 (0.70–2.24)</td>
<td>39</td>
<td>125,268</td>
<td>1.22</td>
<td>1.14 (0.81–1.60)</td>
<td>0.65</td>
</tr>
<tr>
<td>15–19</td>
<td>19</td>
<td>29,849</td>
<td>1.33</td>
<td>1.30 (0.81–2.10)</td>
<td>5</td>
<td>24,001</td>
<td>1.41</td>
<td>1.21 (0.46–3.02)</td>
<td>24</td>
<td>53,850</td>
<td>1.34</td>
<td>1.28 (0.84–1.94)</td>
<td>0.90</td>
</tr>
<tr>
<td>20+</td>
<td>22</td>
<td>47,034</td>
<td>0.90</td>
<td>0.88 (0.56–1.37)</td>
<td>0</td>
<td>6,873</td>
<td>NA</td>
<td>NA</td>
<td>22</td>
<td>53,907</td>
<td>0.84</td>
<td>0.80 (0.51–1.23)</td>
<td>NA</td>
</tr>
<tr>
<td>P trend c</td>
<td>0.97</td>
<td>0.84</td>
<td>0.77</td>
<td>0.78</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.87</td>
</tr>
</tbody>
</table>

a Multivariate analyses adjusted for age (continuous), duration of oral contraceptive use (continuous), parity (continuous), BMI (continuous), smoking status (current/past/never/missing), tubal ligation history (yes/no), menopausal status (postmenopausal/premenopausal or unknown), family history of ovarian cancer (yes/no), duration of breastfeeding (none/≤6 months/7–11 months/12–17 months/18+ months/missing), and cohort (combined analyses only).

b P heterogeneity (P hetero) by cohort was assessed using the DerSimonian and Laird random effects model.

c Value of P for multivariate model including duration of shift work as a continuous variable.
conclusion, increasing duration of rotating night shift work was not associated with ovarian cancer risk in the NHS and NHSII cohorts. However, further exploration of the association between melatonin and risk of ovarian cancer is warranted.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References


Grant Support

The study was supported by National Cancer Institute grants T32 CA009001, P01 CA87969, and R01 CA050385.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received February 3, 2011; revised March 15, 2011; accepted March 17, 2011; published OnlineFirst April 5, 2011.
Rotating Night Shift Work and Risk of Ovarian Cancer

Elizabeth M. Poole, Eva S. Schernhammer and Shelley S. Tworoger

Cancer Epidemiol Biomarkers Prev 2011;20:934-938. Published OnlineFirst April 5, 2011.

Updated version
Access the most recent version of this article at:
doi:10.1158/1055-9965.EPI-11-0138

Cited articles
This article cites 25 articles, 10 of which you can access for free at:
http://cebp.aacrjournals.org/content/20/5/934.full.html#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
/content/20/5/934.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.